跳至主要内容
临床试验/NCT06142656
NCT06142656招募中2 期

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome: A Randomized Clinical Trial

October 6 University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年11月25日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
招募中
入组人数
60
试验地点
1
主要终点
Concentration of luteinizing hormone (LH)

研究概览

简要总结

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.

排除标准

  • Patients with history of diabetes mellitus (Type 1 or 2).
  • Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months
  • Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Eating disorders (anorexia, bulimia) or gastrointestinal disorders

研究组 & 干预措施

Metformin

Active Comparator

干预措施: Metformin Hydrochloride tablet (Drug)

Vildagliptin

Active Comparator

干预措施: Vildagliptin 50 MG (Drug)

结局指标

主要结局

Concentration of luteinizing hormone (LH)

时间窗: at baseline and after 3 months

serum luteinizing hormone (LH)

Concentration of Follicle-stimulating hormone

时间窗: at baseline and after 3 months

Serum Follicle-stimulating hormone

Concentration of Free androgen index

时间窗: at baseline and after 3 months

serum Free androgen index

Concentration of total testosterone

时间窗: at baseline and after 3 months

serum total testosterone

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

engy wahsh

LECTURER OF CLINICAL PHARMACY

October 6 University

研究点 (1)

Loading locations...

相似试验